Breast Tumor Specimen Data Table

1 TUMOR ID NEW YORK 3 STANFORD 14 NORWAY 41 STANFORD 23 NEW YORK 2 NORWAY 109 NORWAY 53 STANFORD 2 NORWAY 57 NORWAY 47 NORWAY 101 STANFORD 37-FA NORWAY 61 NORWAY 65 NORWAY 112 NORWAY 14 STANFORD 17 NORWAY 48 NORWAY 15 NORWAY 7 NORWAY 26 NORWAY 19 NORWAY 11 NORWAY 104 NORWAY 12 NORWAY 100 NORWAY 39 NORWAY 17 NORWAY 10 NORWAY 102 NEW YORK 1 STANFORD 35 STANFORD 38 STANFORD 16 NORWAY 111 STANFORD 24 NORWAY 27 NORWAY 18 NORWAY 16 NORWAY 56

2 ER Clinical negative negative positive negative negative negative positive negative negative positive positive not tested positive negative positive positive positive negative positive positive positive positive positive positive positive positive positive positive positive positive not tested positive positive positive positive positive positive positive positive positive

3 ESR1 Array 0.42 1.25 1.1 0.83 1 0.44 0.93 1 0.88 2.28 0.47 2.25 2.27 8.6 3.35 0.71 9.1 0.81 5.48 6 9.1 7.9 8.65 10.8 31.88 19 12 32.9 4.6 12.3 16 10.93 14.5 21.6 18.9 16.99 29 27.81 18.9 33

4 Erb-B2 Clinical not tested not tested negative negative not tested negative positive positive positive not tested positive not tested positive negative negative negative not tested negative negative negative positive negative positive positive positive negative negative negative negative negative not tested positive positive not tested negative negative negative negative negative negative

5 Erb-B2 Array 3.4 6.1 2.97 1.48 1.7 1.35 21.5 22.6 15.5 9.5 23.3 4.44 12.1 1.52 1.75 8.15 4.6 2.7 1.57 1.9 10.8 1.43 3.3 3.15 3.9 1.45 1.46 2.5 2.2 2.2 2.4 2.47 5.76 1.68 0.87 1.88 2.8 2.32 3.96 1.49

6 Tumor Grade 3 2 3 3 3 3 3 3 3 3 2 3 3 2 2 3 3 2 2 3 3 3 3 3 2 2 2 3 2 3 2 3 3 2 1 2 3 3

7 Differentiation ductal ductal ductal ductal ductal ductal ductal ductal ductal DCIS ductal fibroadenoma lobular ductal ductal ductal ductal ductal ductal ductal ductal ductal ductal ductal ductal ductal ductal ductal lobular ductal ductal ductal ductal ductal ductal ductal ductal ductal ductal ductal

8 Special Notes

1= tumor name as it appears in the figures

2= clinical estrogen receptor status (determined by dextran binding assay and/or immunohistochemistry)

3= average R/G ratio of two independent sequence verified ESR1 clones (the correlation between clinical ER status and the microarray data is best if one calls a R/G ratio of 2.25 or greater "positive" for ER)

4= Erb-B2 clinical status as determined by immunohistochemistry

5= average R/G ratio of four independent sequence verified Erb-B2 clones (the correlation between clinical Erb-B2 status and the microarray data is best if one calls a microarray ratio of 3.15 or greater "positive" for Erb-B2)

6= tumor grade

7= differentiation status

8= additional findings and comments

Last Updated on 05/04/2000
By Charles M. Perou
Email: perou@genome.stanford.edu

1	TUMOR ID	NEW YORK 3	STANFORD 14	NORWAY 41	STANFORD 23	NEW YORK 2	NORWAY 109	NORWAY 53	STANFORD 2	NORWAY 57	NORWAY 47	NORWAY 101	STANFORD 37-FA	NORWAY 61	NORWAY 65	NORWAY 112	NORWAY 14	STANFORD 17	NORWAY 48	NORWAY 15	NORWAY 7	NORWAY 26	NORWAY 19	NORWAY 11	NORWAY 104	NORWAY 12	NORWAY 100	NORWAY 39	NORWAY 17	NORWAY 10	NORWAY 102	NEW YORK 1	STANFORD 35	STANFORD 38	STANFORD 16	NORWAY 111	STANFORD 24	NORWAY 27	NORWAY 18	NORWAY 16	NORWAY 56
2	ER Clinical	negative	negative	positive	negative	negative	negative	positive	negative	negative	positive	positive	not tested	positive	negative	positive	positive	positive	negative	positive	positive	positive	positive	positive	positive	positive	positive	positive	positive	positive	positive	not tested	positive	positive	positive	positive	positive	positive	positive	positive	positive
3	ESR1 Array	0.42	1.25	1.1	0.83	1	0.44	0.93	1	0.88	2.28	0.47	2.25	2.27	8.6	3.35	0.71	9.1	0.81	5.48	6	9.1	7.9	8.65	10.8	31.88	19	12	32.9	4.6	12.3	16	10.93	14.5	21.6	18.9	16.99	29	27.81	18.9	33

4	Erb-B2 Clinical	not tested	not tested	negative	negative	not tested	negative	positive	positive	positive	not tested	positive	not tested	positive	negative	negative	negative	not tested	negative	negative	negative	positive	negative	positive	positive	positive	negative	negative	negative	negative	negative	not tested	positive	positive	not tested	negative	negative	negative	negative	negative	negative
5	Erb-B2 Array	3.4	6.1	2.97	1.48	1.7	1.35	21.5	22.6	15.5	9.5	23.3	4.44	12.1	1.52	1.75	8.15	4.6	2.7	1.57	1.9	10.8	1.43	3.3	3.15	3.9	1.45	1.46	2.5	2.2	2.2	2.4	2.47	5.76	1.68	0.87	1.88	2.8	2.32	3.96	1.49

6	Tumor Grade	3	2	3	3	3	3	3	3	3		3		2	3	3	2	2	3	3	2	2	3	3	3	3	3	2	2	2	3	2	3	2	3	3	2	1	2	3	3
7	Differentiation	ductal	ductal	ductal	ductal	ductal	ductal	ductal	ductal	ductal	DCIS	ductal	fibroadenoma	lobular	ductal	ductal	ductal	ductal	ductal	ductal	ductal	ductal	ductal	ductal	ductal	ductal	ductal	ductal	ductal	lobular	ductal	ductal	ductal	ductal	ductal	ductal	ductal	ductal	ductal	ductal	ductal

8	Special Notes

1= tumor name as it appears in the figures
2= clinical estrogen receptor status (determined by dextran binding assay and/or immunohistochemistry)
3= average R/G ratio of two independent sequence verified ESR1 clones (the correlation between clinical ER status and the microarray data is best if one calls a R/G ratio of 2.25 or greater "positive" for ER)
4= Erb-B2 clinical status as determined by immunohistochemistry
5= average R/G ratio of four independent sequence verified Erb-B2 clones (the correlation between clinical Erb-B2 status and the microarray data is best if one calls a microarray ratio of 3.15 or greater "positive" for Erb-B2)
6= tumor grade
7= differentiation status
8= additional findings and comments